busulfan has been researched along with Nervous System Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maeda, Y | 1 |
| Sasaki, T | 1 |
| Beelen, DW | 1 |
| Sayer, HG | 1 |
| Franke, M | 1 |
| Scheulen, ME | 1 |
| Quabeck, K | 1 |
| Mohnke, M | 1 |
| Oidtmann, M | 1 |
| Schaefer, UW | 1 |
| Erer, B | 1 |
| Polchi, P | 1 |
| Lucarelli, G | 1 |
| Angelucci, E | 1 |
| Baronciani, D | 1 |
| Galimberti, M | 1 |
| Giardini, C | 1 |
| Gaziev, D | 1 |
| Maiello, A | 1 |
| Gallardo, D | 1 |
| Ferrà, C | 1 |
| Berlanga, JJ | 1 |
| Banda, ED | 1 |
| Ponce, C | 1 |
| Salar, A | 1 |
| Alonso, E | 1 |
| Espanñol, I | 1 |
| Riu, C | 1 |
| Grañena, A | 1 |
| Soussain, C | 1 |
| Suzan, F | 1 |
| Hoang-Xuan, K | 1 |
| Cassoux, N | 1 |
| Levy, V | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Leblond, V | 1 |
| Meloni, G | 1 |
| Raucci, U | 1 |
| Pinto, RM | 1 |
| Spalice, A | 1 |
| Vignetti, M | 1 |
| Iannetti, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 review available for busulfan and Nervous System Disorders
| Article | Year |
|---|---|
[Approaches to prevention of the middle to late phase adverse drug reactions in chemotherapy].
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Bleomycin; Busulfan; Doxorubicin; Guideline Adherence; | 2002 |
2 trials available for busulfan and Nervous System Disorders
| Article | Year |
|---|---|
Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Dose-Response R | 1993 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
3 other studies available for busulfan and Nervous System Disorders
| Article | Year |
|---|---|
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood | 1996 |
Neurologic complications after allogeneic bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Abscess; Busulfan; Cerebrovascular Disorders; Cyclosporine; Encep | 1996 |
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Barbiturates; Bone | 1992 |